Pharmaceuticals News and Research

RSS

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

CombinatoRx, Incorporated today announced that the U.S. Food and Drug Administration has approved the New Drug Application (NDA) for Exalgo™ (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time.

2 Mar 2010

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported that the U.S. Food and Drug Administration (FDA) has approved resuming clinical development of elesclomol, the Company's first-in-class oxidative stress inducer.

2 Mar 2010

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

The Greffex Group of regenerative medicine companies announces the signing of a Strategic Alliance Framework Agreement with UPMC and ISMETT, Italy.

2 Mar 2010

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

If you are a parent who has conceived using Ferring Pharmaceuticals' fertility products, you can win a $10,000 education fund to support your child's future. Two other education fund prizes will also be awarded.

2 Mar 2010

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

Simvastatin might help us control our cholesterol, but when it comes to infection, it's an entirely different story says a new research study published in the Journal of Leukocyte Biology. In the research report, scientists from Italy show that simvastatin delivers a one-two punch to the immune system. First it impairs the ability of specialized immune cells, called macrophages, to kill pathogens. Then, it enhances production of molecules, called cytokines, which trigger and sustain inflammation.

2 Mar 2010

Merck's Isentress HIV/AIDS drug pricing: CalSTRS and CalPERS express concern

Today AIDS Healthcare Foundation (AHF) announced that the two largest public pension funds in the nation, the California State Teachers' Retirement System (CalSTRS) and the California Public Employees’ Retirement System (CalPERS), have sent letters to Merck and Co. Pharmaceuticals expressing concern over the company’s pricing for its key HIV/AIDS drug, Isentress—now the most expensive first-line AIDS treatment in the U.S.

2 Mar 2010

Archimedes Pharma raises GBP65 million in new funding

Archimedes Pharma, the leading specialty pharma company, today announced that it has raised GBP65 million (approx US$100 million) in new funding. The round was led by new investor Novo Growth Equity, the growth equity fund of Novo A/S, and included participation by major current investor, Warburg Pincus, a global private equity firm. Archimedes also announced the appointment of a new President and Chief Executive Officer, Jeffrey H. Buchalter, formerly President and Chief Executive Officer of US-based Enzon.

2 Mar 2010

Praxis to provide patient recruitment services for international type 2 diabetes study

Praxis, a company specializing in centralized patient recruitment for clinical research studies, will provide patient recruitment services to a top 20 pharmaceutical company for an international study on type 2 diabetes. The study explores an investigational drug’s effectiveness for maintaining glycemic control for individuals newly diagnosed with type 2 diabetes.

2 Mar 2010

WuXi PharmaTech, JANSSEN division announce collaboration for preclinical services

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V. (JANSSEN), to collaborate in the area of preclinical services.

2 Mar 2010

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

A newly identified cancer biomarker could define a new subtype of breast cancer as well as offer a potential way to treat it, say researchers at Washington University School of Medicine in St. Louis. Their findings will be published in the March 1 online early edition issue of the Proceedings of the National Academy of Sciences.

2 Mar 2010

Study: EIB may affect lives and health of public if not addressed properly

For the vast majority of the general public, respiratory symptoms such as shortness of breath, wheezing or coughing are a common part of the exercise experience. However, together with chest tightness, noisy breathing and trouble taking a deep breath, these six symptoms make up the phenomenon known as exercise-induced bronchospasm (EIB), which has physical, emotional and psychological consequences if not addressed properly.

2 Mar 2010

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

The Research Partnership in Cognitive Aging, a public-private effort to promote the study of brain function with age, will award up to $28 million over five years to 17 research grants to examine the neural and behavioral profiles of healthy cognitive aging and explore interventions that may prevent, reduce or reverse cognitive decline in older people.

2 Mar 2010

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Canyon PharmaceuticalsTM (www.canyonpharma.com) today announced the availability of Iprivask (desirudin for injection), the first direct thrombin inhibitor (DTI) approved in the United States by the Food and Drug Administration for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism in patients undergoing elective hip replacement surgery.

2 Mar 2010

Agilent Technologies announces new lab informatics suite at Pittcon 2010

Agilent’s major new lab informatics suite, the OpenLAB portfolio, is designed to enable customers to easily capture, analyze and share scientific data throughout the lab and across the enterprise. OpenLAB is scalable, open architecture based on industry open standards.

2 Mar 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.

2 Mar 2010

PTSD drug: Cannabis Science to file first application for FDA clinical trials

Cannabis Science Inc., a pharmaceutical cannabis company in the US, is pleased to announce that it now has the results of its survey of more than 1,300 individuals with PTSD, including a large cohort of veterans. The survey was conducted by Cannabis Science Advisory Board member Dr. Mitch Earleywine PhD. of the State University of New York (Albany).

2 Mar 2010

Nuclear Regulatory Commission licenses Positron facility in Fishers to handle radioactive material

Positron Corporation a molecular imaging solutions company focused on Nuclear Cardiology, announced today that the Nuclear Regulatory Commission has licensed the Positron facility in Fishers, Indiana to handle radioactive material.

2 Mar 2010

Watson Pharmaceuticals agrees to divest equity ownership position in ScinoPharm Taiwan

Watson Pharmaceuticals, Inc. today announced that it signed an agreement on February 26, 2010 to divest its equity ownership position of approximately 31% of ScinoPharm Taiwan Ltd. The transaction is subject to the parties obtaining approvals from various government agencies in Taiwan, as well as other customary closing conditions.

2 Mar 2010

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

ARIAD Pharmaceuticals, Inc. today announced that its investigational pan-BCR-ABL inhibitor, AP24534, has been granted orphan drug designation by both the U. S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In the U.S., the orphan designation of AP24534 is for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and in the E.U., its orphan designation is for CML and acute lymphoblastic leukemia.

2 Mar 2010

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today the dosing of the first patient in a Phase I study of the investigational neuroprotective agent, QPI-1007.

2 Mar 2010

Pharmaceuticals News and Research

FDA approves CombinatoRx's NDA for Exalgo extended-release tablets

Synta Pharmaceuticals receives FDA approval for resuming elesclomol clinical development

Greffex Group signs Strategic Alliance Framework Agreement with UPMC and ISMETT

My Little Miracle Essay Contest: Winners to receive education fund prizes to support their children's future

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

Merck's Isentress HIV/AIDS drug pricing: CalSTRS and CalPERS express concern

Archimedes Pharma raises GBP65 million in new funding

Praxis to provide patient recruitment services for international type 2 diabetes study

WuXi PharmaTech, JANSSEN division announce collaboration for preclinical services

New class of breast cancer: Overexpression of LRP6 gene could be a potential marker

Study: EIB may affect lives and health of public if not addressed properly

$28M grant to examine neural and behavioral profiles of healthy cognitive aging

Canyon Pharmaceuticals announces the availability of Iprivask inhibitor for prevention of DVT

Agilent Technologies announces new lab informatics suite at Pittcon 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

PTSD drug: Cannabis Science to file first application for FDA clinical trials

Nuclear Regulatory Commission licenses Positron facility in Fishers to handle radioactive material

Watson Pharmaceuticals agrees to divest equity ownership position in ScinoPharm Taiwan

ARIAD Pharmaceuticals' investigational pan-BCR-ABL inhibitor receives FDA and EMA orphan drug designation

Quark Pharmaceuticals commences dosing in clinical study of QPI-1007 for NAION

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence